SCHEMBL6522510

SCHEMBL6522510

O=C1Nc2ccc(Br)cc2/C1=C\c1ccc2[nH]nnc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 3/20 0.61
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
MAP1LC3B Q9GZQ8 1/20 0.53
PDGFRB P09619 2/20 0.50
RPS6KA3 P51812 1/20 0.49
RET P07949 1/20 0.48
PLK1 P53350 1/20 0.47
LRRK2 Q5S007 2/20 0.46
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
FGFR1 P11362 1/20 0.45
SRC P12931 1/20 0.45
KDR P35968 1/20 0.45
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6522514 1.00 PLK4 (0.61) PLK4MEN1KMT2AMAP1LC3BPDGFRB
SCHEMBL6525485 0.86 RET (0.57) PLK4RPS6KA3RETLRRK2PSEN1
SCHEMBL6525491 0.86 RET (0.57) PLK4RPS6KA3RETLRRK2PSEN1
SCHEMBL6522938 0.85 PDGFRB (0.54) PLK4MEN1KMT2APDGFRBRET
SCHEMBL6522946 0.85 PDGFRB (0.54) PLK4MEN1KMT2APDGFRBRET
SCHEMBL6520566 0.80 RET (0.53) PLK4PDGFRBRPS6KA3RETLRRK2
SCHEMBL6520557 0.80 RET (0.53) PLK4PDGFRBRPS6KA3RETLRRK2
SCHEMBL6523868 0.80 MGAM (0.52) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL6523877 0.80 MGAM (0.52) LRRK2PSEN1PSEN2APH1BNCSTN
SCHEMBL6521286 0.80 PLK4 (0.62) PLK4MEN1KMT2AMAP1LC3BPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 PLK4 464/4885MEN1 3149/4885KMT2A 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.